HC Wainwright Has Strong Estimate for Korro Bio Q3 Earnings

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Korro Bio to a loss of $1.12 per share from a previous estimate of $1.38, while maintaining a Buy rating and $15 price target.
• Korro Bio’s latest quarterly results beat expectations, with an adjusted loss of $1.07 per share versus the $1.34 consensus estimate and revenue of $1.50 million compared with the $0.21 million forecast.
• Analyst sentiment is generally positive, with the stock carrying a Moderate Buy consensus rating and an average price target of $16.71; shares opened at $13.49 and have ranged from $5.20 to $55.89 over the past year.

Korro Bio, Inc. (NASDAQ:KRRO - Free Report) - Research analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Korro Bio in a report released on Friday, August 7th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings per share of ($1.12) for the quarter, up from their prior estimate of ($1.38). HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Korro Bio's current full-year earnings is ($5.14) per share. HC Wainwright also issued estimates for Korro Bio's Q4 2026 earnings at ($1.16) EPS, FY2026 earnings at ($4.88) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.22) EPS, Q3 2027 earnings at ($1.26) EPS, Q4 2027 earnings at ($1.31) EPS and FY2027 earnings at ($5.04) EPS.

A number of other brokerages also recently issued reports on KRRO. JonesTrading raised Korro Bio from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 8th. Citigroup assumed coverage on shares of Korro Bio in a report on Monday, May 18th. They set a "buy" rating and a $21.00 price objective on the stock. Wall Street Zen raised shares of Korro Bio from a "strong sell" rating to a "sell" rating in a report on Saturday. Lifesci Capital raised shares of Korro Bio to a "strong-buy" rating in a report on Friday, May 29th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Korro Bio in a research report on Monday, July 6th. Three analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Korro Bio currently has an average rating of "Moderate Buy" and a consensus target price of $16.71.

Korro Bio Stock Up 1.8%

Shares of Korro Bio stock opened at $13.49 on Tuesday. The company has a market cap of $198.71 million, a P/E ratio of -1.35 and a beta of 3.04. The firm's 50 day moving average price is $12.20 and its 200-day moving average price is $12.12. Korro Bio has a 52-week low of $5.20 and a 52-week high of $55.89.

Korro Bio (NASDAQ:KRRO - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.07) earnings per share for the quarter, beating analysts' consensus estimates of ($1.34) by $0.27. The company had revenue of $1.50 million for the quarter, compared to the consensus estimate of $0.21 million. Korro Bio had a negative return on equity of 114.26% and a negative net margin of 1,834.48%.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in shares of Korro Bio during the second quarter worth $10,776,000. Affinity Asset Advisors LLC purchased a new position in shares of Korro Bio in the first quarter worth about $8,002,000. Nantahala Capital Management LLC acquired a new position in Korro Bio during the fourth quarter worth about $4,806,000. ADAR1 Capital Management LLC acquired a new position in Korro Bio during the first quarter worth about $6,113,000. Finally, TCG Crossover Management LLC purchased a new stake in Korro Bio during the 3rd quarter valued at about $19,937,000. 13.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Korro Bio

In other news, COO Todd Chappell sold 3,168 shares of the firm's stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $10.83, for a total value of $34,309.44. Following the transaction, the chief operating officer owned 16,964 shares in the company, valued at $183,720.12. This trade represents a 15.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jean Francois Formela sold 119,005 shares of the firm's stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $14.25, for a total value of $1,695,821.25. Following the completion of the transaction, the director owned 176,649 shares in the company, valued at approximately $2,517,248.25. This trade represents a 40.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 306,026 shares of company stock valued at $4,309,637. 4.80% of the stock is owned by corporate insiders.

Korro Bio Company Profile

Korro Bio, Inc is a clinical-stage biotechnology company focused on harnessing advanced protein engineering and synthetic biology to develop novel enzyme therapies and live microbial therapeutics. The company's proprietary platform integrates directed evolution, high-throughput screening and computational design to optimize biological catalysts for a wide range of applications. By combining machine learning with experimental biology, Korro Bio seeks to accelerate the discovery and development of next-generation treatments for rare genetic disorders and complex metabolic diseases.

The company's pipeline features both engineered enzyme therapeutics and live biotherapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source